Please join us on Thursday, January 12 at 5:00 pm EST (4:00 pm CST/2:00 pm PST) for a webinar about the HEALEY ALS Platform Trial. Sabrina Paganoni, MD, PhD, and Merit Cudkowicz, MD, MSc will present updates on the Platform Trial and answer questions from the audience. In addition, we will be joined by guest speakers Michael Hotchkin (Chief Development Officer at Clene Nanomedicine, Inc) and James Berry, MD, MPH (Regimen C co-Lead, Mass General Hospital) to discuss the latest news and updates regarding Regimen C.
Regimen C is evaluating the investigational product CNM-Au8, developed by Clene Nanomedicine, Inc. The topline results for Regimen C were announced in October 2022, click hereto read the press release or click hereto view the recorded webinar discussion.